Genetic targets in pediatric acute lymphoblastic leukemia

Research output: Chapter in Book/Report/Conference proceedingChapter

15 Scopus citations

Abstract

Acute leukemia represents 31% of all cancers diagnosed in children and 80% of it is of Lymphoblastic type. Multiple genetic lesions in the hematopoietic progenitor cells prior to or during differentiation to B and T cell lead to development of leukemia. There are several subtypes of Acute Leukemia based on chromosome number changes, the presence of certain translocations and gene mutations, each of which has different clinical, biological and prognostic features. High throughput genomic technologies like array-based comparative genomic hybridization (array-CGH) and single nucleotide polymorphism microarrays (SNP arrays), have given us insight through a very detailed look at the genetic changes of leukemia, specifically, ALL. Here, we discuss various genetic mutations identified in Acute Lymphoblastic Leukemia. We also explore various genetic targets and currently available as well as upcoming targeted therapies for ALL.

Original languageEnglish (US)
Title of host publicationImpact of Genetic Targets on Cancer Therapy
PublisherSpringer Science and Business Media, LLC
Pages327-340
Number of pages14
ISBN (Print)9781461461753
DOIs
StatePublished - 2013

Publication series

NameAdvances in Experimental Medicine and Biology
Volume779
ISSN (Print)0065-2598

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Genetic targets in pediatric acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this